NEUROPHET Inc.
Financials
Valuation Metrics
NEUROPHET Inc.'s Market Cap is ₩987B. Ranked #1253 of 2,436 in KR market (top 51%), #676 of 1,649 on KOSDAQ (top 41%), #48 of 96 in Health Care Equipment & Services (top 50%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 98.69B KRW | KR#1,253/2,436 Sec#48/96 |
| Revenue | 2.62B KRW | KR#2,382/2,436 Sec#96/96 |
| Net Income | -22.39B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 26.88B KRW | KR#2,341/2,436 Sec#90/96 |
| Net Assets | 19.45B KRW | KR#2,287/2,436 Sec#89/96 |
| Value | ||
| P/B | 5.07x | KR#2,240/2,436 Sec#83/96 |
| P/S | 37.74x | KR#2,359/2,436 Sec#93/96 |
| FCF Yield | -15.54% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | -115.10% | KR#2,354/2,436 Sec#92/96 |
| ROA | -83.28% | KR#2,381/2,436 Sec#95/96 |
| Op. Margin | -632.84% | KR#2,380/2,436 Sec#95/96 |
| Financial Health | ||
| Debt Ratio | 138.21% | KR#1,003/2,436 Sec#47/96 |
| Total Debt | 4.80B KRW | KR#1,790/2,436 Sec#64/96 |
| FCF | -15.33B KRW | KR#1,835/2,436 Sec#72/96 |
| Cash | 4.10B KRW | KR#2,063/2,436 Sec#75/96 |
| Current Ratio | 3.61x | KR#494/2,436 Sec#30/96 |
| Performance | ||
| 1Y Return | -46.10% | KR#1,990/2,436 Sec#71/96 |
| 1M Return | -18.28% | KR#2,141/2,436 Sec#83/96 |
| From 52W High | -77.96% | KR#2,330/2,436 Sec#92/96 |
| 1Y MDD | -83.11% | KR#2,345/2,436 Sec#93/96 |
| Trading | ||
| Volume | 86,536 shares | KR#1,019/2,436 Sec#41/96 |
| Foreign Own. | 0.62% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | -2,107 KRW | KR—/2,436 Sec—/96 |
| BPS | 1,571 KRW | KR#2,145/2,436 Sec#75/96 |
Company Info
Neurophit was established in 2016 as a specialized AI solution company for brain diseases and is scheduled to be listed on KOSDAQ in 2025. The company develops AI technology-based brain image analysis software and therapeutic medical devices, providing full-cycle brain disease medical solutions from diagnosis to treatment. Neurophit possesses AQUA for degenerative brain disease diagnosis support, SCALE PET for PET image analysis, and AQUA AD for Alzheimer's solutions, while continuously conducting R&D in various brain disease fields such as depression treatment and brain MRI. Neurophit is headquartered in Gangnam-gu, Seoul.